Navigation Links
IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
Date:11/8/2013

SANTA MONICA, Calif., CLEVELAND and CAESAREA, Israel, Nov. 8, 2013 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) announced today that the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, CA, treated its first breast cancer patient using the IceSense3 Cryoablation System in a pilot study evaluating immune responses in patients with operable breast cancer. In this pilot study, patients undergo cryoablation of their breast cancer before surgery and blood draws at their scheduled office visits.

(Photo:  http://photos.prnewswire.com/prnh/20130507/CL09547 )

To understand the immune response, JWCI researchers are studying the make-up of immune cells and factors within the breast cancer and blood after cryoablation. It is hoped that understanding the immune response elicited by cryoablation will provide information on the mechanisms important for the development of tumor immunity.

"We are excited about this study and the knowledge we will gain regarding how cancers evade the immune system and mechanisms to overcome this resistance," said Maureen Chung, MD, PhD, FACS, Director of Saint John's Margie Petersen Breast Center and JWCI's Margie and Robert E. Petersen Breast Cancer Research Program. "Among several criteria to be eligible for this study, patients must be candidates for breast cancer surgery and the cancer must be visible by ultrasound."

This clinical trial is supported in part by funds donated by the Fashion Footwear Association of New York Charitable Foundation. IceCure neither sponsors nor funds this clinical trial.

"One of our goals is to support investigator-initiated studies of cryoablation in cancer and data collection, which is the first step in potentially making cryoablation available for the treatment of cancer," stated Hezi Himelfarb, President and CEO of IceCure Medical.

Cryoablation is the technique of using extreme cold to destroy tissue. It has been used for years in medical applications such as dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors. The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA-approval for benign and malignant disease.

About John Wayne Cancer Institute
Since 1981, the John Wayne name has been committed by the Wayne family to groundbreaking cancer research and education in memory of their father, who died of cancer. The John Wayne Cancer Institute has received worldwide acclaim for advances in melanoma (skin cancer), breast and colon cancer as well as for immune therapy of cancer. Other areas of research include prostate and liver cancer. With its unique ability to rapidly turn scientific breakthroughs into innovative approaches to treatment and early detection, the Institute provides immediate hope to cancer patients around the globe. For more information, visit www.jwci.org.

About Saint John's Health Center
Since its founding in 1942 by the Sisters of Charity of Leavenworth, Saint John's Health Center has been providing the patients and families of Santa Monica, West Los Angeles and ocean communities with breakthrough medicine and inspired healing. Saint John's provides a spectrum of treatment and diagnostic services with distinguished areas of excellence in cancer care, spine, orthopedics, women's health, cardiac care and specialized programs such as the internationally acclaimed John Wayne Cancer Institute. Saint John's is dedicated to bringing to the community the most innovative advances in medicine and technology. For more information, visit us at www.newstjohns.org, like us at www.facebook.com/NewSaintJohns or follow us at www.twitter.com/SaintJohns2.

About IceCure Medical
IceCure Medical, is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit www.icecure-medical.com.Contact:

Sarah Phelan

Will IrbySaint John's/JWCI

IceCure Medical, Inc.(310) 315-4054

(901) 237-4630(818) 929-4784 (cell)

wirby@icecure-medical.comsarah.phelan@stjohns.org 


'/>"/>
SOURCE IceCure Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer
2. Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
3. Quest International Appointed As Authorized Reseller For Sony Electronics Medical Systems Division
4. Call for Entries - 2014 Medical Design Excellence Awards
5. Aethlon Medical to Present at SeeThruEquity Investor Conference
6. Ariosa Diagnostics Appoints Dan Puckett as Chief Financial Officer and Dr. Thomas Musci as Chief Medical Officer
7. Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. Quantum Materials Engineers Tetrapod Quantum Dots to Improve Diagnostic Accuracy of Biomedical Assays and Devices
9. NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
10. Paxeramed debuts industrys first social-media medical images sharing module
11. Cantel Medical Acquires Jet Prep Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):